OLIVIA LEE: Open Payments
NPI 1821741331 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$333 in 20 payments from 12 companies in 2025. Trend: 2023 $150 · 2024 $211 · 2025 $333
Food & beverage: $333
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $73 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| Novo Nordisk Inc | 2 | $38 |
| SANOFI-AVENTIS U.S. LLC | 1 | $28 |
| Evofem Biosciences, Inc. | 3 | $24 |
| Invivyd Inc | 1 | $20 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| TriSalus Life Sciences, Inc. | 1 | $17 |
| Alexion Pharmaceuticals, Inc. | 1 | $15 |
Products named: ZEPBOUND, Ozempic, Fabhalta, THYMOGLOBULIN, Phexxi, Vanrafia, PEMGARDA, IQIRVO.
Industry payments across GA — which companies pay providers there.
